溶酶体相关膜蛋白3研究揭示溶酶体在干燥病病理生理与治疗中的作用
本文综述溶酶体相关膜蛋白3(LAMP3)在干燥病(SjD)发病机制中的核心作用。LAMP3由I型干扰素(IFN)信号诱导并在唾液腺上皮细胞(SGECs)中异位表达,经Toll样受体7(TLR7)活化进一步放大,通过促进水通道蛋白5(AQP5)和钠-钾-氯共转运体1的溶酶体降解、介导损伤相关分子模式(DAMPs)的溶酶体胞吐增强单核细胞骨形态发生蛋白6(BMP6)产生、驱动自身抗原的细胞外囊泡释放及溶酶体依赖性细胞死亡,导致腺体分泌功能受损。LAMP3被视为SjD发病的关键调控枢纽和潜在治疗靶点。
要点
- LAMP3在SGECs中由I型IFN信号诱导异位表达,并经TLR7活化进一步放大。
- LAMP3促进AQP5和钠-钾-氯共转运体1的溶酶体降解,导致液体分泌受损。
- LAMP3介导DAMPs溶酶体胞吐增强单核细胞BMP6产生,进而抑制AQP5转录。
核心结论
- LAMP3是连接IFN/TLR7信号、溶酶体功能障碍与腺体功能低下的SjD发病关键调控枢纽,使其成为有吸引力的治疗靶点。
研究设计与样本
- 本文为综述,围绕LAMP3在SjD病理生理与治疗中的作用进行阐述,原文未报告系统检索范围。
主要发现
- LAMP3在SGECs中的异位表达由I型IFN信号诱导,并经TLR7活化进一步放大。
- LAMP3异常上调通过促进AQP5和钠-钾-氯共转运体1的內溶酶体降解,导致液体分泌受损及相关临床后遗症(如口干)。
- LAMP3介导的DAMPs溶酶体胞吐增强单核细胞BMP6产生,BMP6进而抑制AQP5转录。
- LAMP3驱动自身抗原的细胞外囊泡介导释放,进一步放大自身免疫,SGECs中溶酶体依赖性细胞死亡参与组织损伤。
关键数值与推荐
- 原文汇总的治疗策略包括:IFN和TLR7通路抑制剂以限制LAMP3诱导、恢复溶酶体功能、抑制BMP6以保护AQP5表达、AQP5基因治疗以改善液体分泌。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lysosome-associated membrane protein 3 (LAMP3) is a unique lysosomal membrane protein specifically expressed in mature dendritic cells and type II pneumocytes. Its ectopic expression in salivary gland epithelial cells (SGECs) is induced by type I interferon (IFN) signaling and is further amplified through Toll-like receptor 7 (TLR7) activation, which is implicated in the pathogenesis of Sjögren disease (SjD). This aberrant up-regulation disrupts glandular function by promoting endolysosomal degradation of aquaporin 5 (AQP5) and sodium-potassium-chloride cotransporter 1, leading to impaired fluid secretion and associated clinical sequelae (eg, dry mouth). Additionally, LAMP3-mediated lysosomal exocytosis of DAMPs enhances monocytic bone morphogenetic protein 6 (BMP6) production, which in turn suppresses AQP5 transcription. Moreover, LAMP3 drives the extracellular vesicle-mediated release of autoantigens, which further amplifies autoimmunity, and lysosome-dependent cell death in SGECs contributes to tissue damage. These findings establish LAMP3 as a pivotal regulatory hinge in SjD pathogenesis, linking IFN/TLR7 signaling, lysosomal dysfunction, and glandular hypofunction. Its central role makes it a compelling therapeutic target, with strategies including IFN and TLR7 pathway inhibitors to limit its induction, restoration of lysosomal function, BMP6 inhibition to preserve AQP5 expression, and AQP gene therapy to improve fluid secretion.
引用
- Nakamura H, Tanaka T, Noguchi M, et al. Investigation of Lysosome-Associated Membrane Protein 3 Highlighting the Role of Lysosome in Pathophysiology and Treatment of Sjögren Disease. Arthritis Rheumatol. 2025. PMID: 40757483. doi:10.1002/art.43347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。